Analysts Offer Insights on Real Estate Companies: Scentre Group (OtherSTGPF), Omega Healthcare (OHI) and Stockland (OtherSTKAF)
Analysts fell to the sidelines weighing in on Scentre Group (STGPF – Research Report), Omega Healthcare (OHI – Research Report) and Stockland (STKAF – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Scentre Group (STGPF)
In a report released today, Solomon Zhang from UBS maintained a Hold rating on Scentre Group, with a price target of A$4.20. The company’s shares closed last Tuesday at $2.70.
According to TipRanks.com, Zhang is a 4-star analyst with an average return of
Scentre Group has an analyst consensus of Hold, with a price target consensus of $2.99.
See Insiders’ Hot Stocks on TipRanks >>
Omega Healthcare (OHI)
In a report released today, Juan C. Sanabria from BMO Capital maintained a Hold rating on Omega Healthcare, with a price target of $45.00. The company’s shares closed last Wednesday at $42.96, close to its 52-week high of $44.42.
According to TipRanks.com, Sanabria is a 2-star analyst with an average return of
Omega Healthcare has an analyst consensus of Moderate Buy, with a price target consensus of $47.56, a 10.1% upside from current levels. In a report issued on January 29, Wells Fargo also downgraded the stock to Hold with a $45.00 price target.
Stockland (STKAF)
In a report released today, Cody Shield from UBS maintained a Hold rating on Stockland, with a price target of A$5.82. The company’s shares closed last Friday at $3.76, close to its 52-week high of $3.86.
According to TipRanks.com, Shield is a 3-star analyst with an average return of
Stockland has an analyst consensus of Moderate Buy, with a price target consensus of $4.40, implying a 17.0% upside from current levels. In a report issued on January 27, Macquarie also maintained a Hold rating on the stock with a A$5.45 price target.
